$3.52
+0.00 (+0.00%)
Open$3.49
Previous Close$3.52
Day High$3.55
Day Low$3.41
52W High$29.98
52W Low$3.52
Volume—
Avg Volume57.8K
Market Cap35.29M
P/E Ratio—
EPS$-2.33
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+631.0% upside
Current
$3.52
$3.52
Target
$25.73
$25.73
$18.91
$25.73 avg
$33.51
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 867.7K | 3.06M | 47.44M |
| Net Income | 6.26M | 19.85M | 5.52M |
| Profit Margin | 721.9% | 685.8% | 11.6% |
| EBITDA | -10,060,019 | -33,675,186 | 8.75M |
| Free Cash Flow | — | — | 3.59M |
| Rev Growth | -71.6% | -71.6% | +12.6% |
| Debt/Equity | — | — | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |